NCT06650748 2026-03-17
NeoMARS
Peking University
Phase 2 Enrolling by invitation
Clinical Trials
3 trialsNCT06970912 2026-01-21
DNADalHR
Peking University People's Hospital
Phase 2 Recruiting
NCT07307287 2025-12-29
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting